Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro

References

• Barbui C, Hotopf M. 2001. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry. 178:129–144.
   PubMed Web of Science ®Google Scholar
• Brosen K. 2004. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 59:5–12.
   PubMed Web of Science ®Google Scholar
• Cai J, Dai DP, Geng PW, Wang SH, Wang H, Zhan YY, Huang XX, Hu GX, Cai JP. 2016. Effects of 22 novel CYP2D6 variants found in the Chinese population on the bufuralol and dextromethorphan metabolisms in vitro. Basic Clin Pharmacol Toxicol. 118: 190–199.
   Google Scholar
• Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC. 1999. The texas medication algorithm project: report of the texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry. 60:142–156.
   PubMed Web of Science ®Google Scholar
• Dai DP, Geng PW, Wang SH, Cai J, Hu LM, Nie JJ, Hu JH, Hu GX, Cai JP. 2015. In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. Basic Clin Pharmacol Toxicol. 117:39–43.
   PubMed Web of Science ®Google Scholar
• Funae Y, Kishimoto W, Cho T, Niwa T, Hiroi T. 2003. CYP2D in the brain. Drug Metab Pharmacokinet. 18:337–349.
   PubMedGoogle Scholar
• Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR. 2014. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 22:1807–1814.
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G. 2008. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 30:474–482.
   PubMed Web of Science ®Google Scholar
• Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Müller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML. 2004. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 60:329–336.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Hanna IH, Martin MV, Gillam EM. 2003. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry. 42:1245–1253.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 25:193–200.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5:6–13.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. 2007. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 116:496–526.
   PubMed Web of Science ®Google Scholar
• Kulaksiz-Erkmen G, Dalmizrak O, Dincsoy-Tuna G, Dogan A, Ogus IH, Ozer N. 2013. Amitriptyline may have a supportive role in cancer treatment by inhibiting glutathione S-transferase pi (GST-pi) and alpha (GST-alpha). J Enzyme Inhib Med Chem. 28:131–136.
   PubMed Web of Science ®Google Scholar
• Kwadijk-De Gijsel S, Bijl MJ, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Ch Stricker BH. 2009. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. Br J Clin Pharmacol. 68:221–225.
   PubMed Web of Science ®Google Scholar
• Marechal JD, Kemp CA, Roberts GC, Paine MJ, Wolf CR, Sutcliffe MJ. 2008. Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions. Br J Pharmacol. 153:S82–S89.
   PubMed Web of Science ®Google Scholar
• Niwa T, Murayama N, Yamazaki H. 2011. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr Drug Metab. 12:412–435.
   PubMed Web of Science ®Google Scholar
• Qian JC, Xu XM, Hu GX, Dai DP, Xu RA, Hu LM, Li FH, Zhang XH, Yang JF, Cai JP. 2013. Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics. 14:1731–1743.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy Y, Tyndale RF, Sellers EM. 2001. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 11:477–487.
   PubMedGoogle Scholar
• Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T. 2004. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants – a pilot study. Clin Pharmacol Ther. 75:386–393.
   PubMed Web of Science ®Google Scholar
• Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 34:83–448.
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. 2006. Crystal structure of human cytochrome P450 2D6. J Biol Chem. 281:7614–7622.
   PubMed Web of Science ®Google Scholar
• Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, Li C. 2007. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos. 35:1292–300.
   PubMed Web of Science ®Google Scholar
• Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, et al. 2010. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 11:537–546.
   PubMed Web of Science ®Google Scholar
• Yu A, Kneller BM, Rettie AE, Haining RL. 2002. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther. 303:1291–1300.
   PubMed Web of Science ®Google Scholar
• Zhou SF. 2009. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 48:689–723.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 41:89–295.
   PubMed Web of Science ®Google Scholar